Unlocking the Proteome for Precision Medicine
TargetX builds a proteomics-first platform to accelerate TPD drug discovery, deliver AI-driven clinical diagnostics, and provide world-class analytical services—powered by ID-Free AI Proteomics that utilizes 100% of MS/MS data, and proprietary Kinase Landscape Scanning (KLS) for zero-blind-spot TPD development, and, Mutually Independent Dual Online LC and 2D-NCFC LC.
Our Technology
Proprietary platforms overcoming the limits of traditional proteomics.
Kinome-Wide insight for TPD success. Quantifies over 500 kinases endogenously to predict toxicity and elucidate MoA.
Learn More →Unrivaled depth and sensitivity via Zero MS Dead Time Analysis and NCFC 2D Separation systems.
Learn More →Analyzing "dark" MS/MS data to unlock the future of cancer screening and multi-cancer early detection.
Learn More →Making proteomics the operating system of precision medicine.
We are dedicated to providing the functional context needed to treat diseases with unprecedented accuracy through innovative technology and AI.
Learn More About Our MissionPrecision at Scale
Industry-leading depth and sensitivity across our platform.
500+
Kinases Quantified
13k+
Proteins Identified
100k+
Phosphopeptides
2x
MS Throughput
Clinical Diagnostics
Beyond DNA, Into the Proteome. Delivering AI-driven clinical insights for early detection and subtyping.
Precision Oncology
Predict prognosis by classifying molecular subtypes not visible through genomics alone.
Learn More →MCED
Detect cancers early through fast & information-rich liquid biopsy using advanced proteomics.
Learn More →Ready to Accelerate Your Discovery?
We provide premier CRO services for global pharma and research institutes, specializing in TPD, MoA analysis, and ultra-deep phosphoproteomics.
View Our Services